ICOSL Polypeptide Therapy for Proteinuric Kidney Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aberrant activation of αvβ3 integrin on podocytes contributes to the pathogenesis of proteinuric kidney diseases such as focal and segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN), with existing treatments focusing on antagonist therapy which may have limitations.
Innovation Solution
Administration of a therapeutically effective amount of inducible co-stimulator ligand (ICOSL) polypeptide to counteract activated αvβ3 integrin, leveraging its direct binding capability through the RGD motif to modulate integrin signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If antagonist therapy is used to block αvβ3 integrin activation, then proteinuria and kidney fibrosis are reduced, but treatment complexity and potential side effects increase
Solution Approach 1:
The patent uses ICOSL, a naturally occurring protein that endogenously binds to and counteracts activated αvβ3 integrin. Instead of introducing complex synthetic antagonists, the invention leverages the body's own ICOSL protein (or recombinant versions) to achieve therapeutic effects, simplifying the treatment approach while maintaining efficacy against proteinuria and kidney fibrosis
Solution Approach 2:
The invention exploits the natural protective role of ICOSL that already exists in the kidney. By administering ICOSL (which the body can produce or respond to), the treatment activates an endogenous protective mechanism rather than introducing foreign complex molecules, thereby reducing treatment complexity while effectively reducing harmful integrin activation effects
2Reliability
If ICOSL is administered to counteract activated αvβ3 integrin, then kidney function is protected, but understanding of ICOSL's mechanism is limited since it was previously considered an exclusively single receptor-ligand pair
Solution Approach 1:
The patent identifies ICOSL as an intermediary molecule that bridges the gap between immune signaling and integrin regulation. By demonstrating that ICOSL binds to αvβ3 integrin through its RGD motif, the invention reveals a dual-function mechanism where ICOSL serves both its traditional costimulatory role and a new protective role in counteracting aberrant integrin activation, thereby expanding mechanistic understanding while maintaining therapeutic reliability
3Reliability
If existing antagonist treatments are used for proteinuric kidney diseases, then disease progression is slowed, but the treatments may have limitations in efficacy and safety
Solution Approach 1:
The patent changes the therapeutic parameter from synthetic integrin antagonists to ICOSL protein therapy. This parameter change leverages the natural binding affinity and specificity of ICOSL for activated αvβ3 integrin, providing improved efficacy and safety profiles compared to existing antagonists. The ICOSL treatment achieves better adaptability by naturally responding to the activation state of integrins without the limitations of synthetic molecule design
Solution Approach 2:
The invention utilizes the composite nature of ICOSL, which contains both the costimulatory domain (for immune regulation) and the RGD motif (for integrin binding). This composite structure allows ICOSL to simultaneously engage multiple pathways, providing enhanced therapeutic versatility and safety compared to single-function antagonists, while effectively controlling disease progression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ICOSL effectively reduces proteinuria and kidney fibrosis by blocking the negative effects of activated αvβ3 integrin, demonstrating a protective role in maintaining kidney function and structure.
Implementation Method 1
ICOSL, through its RGD motif, directly bound αvβ3 integrin
Data Source
AI summary
Methods treating an aberrant activation of αvβ integrin are provided. The methods include administering a therapeutically effective amount of inducible co-stimulator ligand (ICOSL) polypeptide to a subject in need thereof. Methods of identifying subjects having a kidney injury are also provided.